BCM
TEVA icon

Berbice Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Berbice Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-700
Closed -$21.1K – 153
2026
Q1 		$21.1K Buy
+700
New +$22.5K 0.01% 109
2025
Q2 		– Sell
-400
Closed -$6.15K – 192
2025
Q1 		$6.15K Buy
+400
New +$7.14K 0.01% 161

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Berbice Capital Management's TEVA Position: Q2 2026 in Review

Berbice Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 700 shares — an estimated $21.1K sold.

Berbice Capital Management first reported a position in TEVA in Q1 2025 and held it in 2 quarters. The position peaked at $21.1K in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Berbice Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Berbice Capital Management sold 700 Teva Pharmaceuticals shares in Q2 2026, an estimated $21.1K.
  • Berbice Capital Management first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Berbice Capital Management's Teva Pharmaceuticals position peaked at $21.1K in Q1 2026.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Berbice Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.